The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The Graft vs Host Disease Market has been comprehensively analyzed in IMARC's new report titled "Graft vs Host Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast". Graft versus host disease (GvHD) refers to a condition that can occur after an allogeneic transplant. GvHD develops when donated bone marrow or peripheral blood stem cells perceive the recipient's body as foreign and attack the body. Acute graft versus host disease (aGvHD) and chronic graft versus host disease (cGvHD) are the two main types of GvHD. Acute and chronic GvHD both have modest to severe symptoms. Acute GvHD typically manifests within a few days or even up to six months following a transplant. The most afflicted organs are the skin, liver, intestines, and immune system. Jaundice (yellowing of the skin or eyes) or other liver disorders, skin rash, itching, and redness on specific parts of the skin are examples of common acute symptoms. A lifetime of chronic GvHD is possible and typically begins more than three months following a transplant. Chronic symptoms may include dry eyes, burning sensation, vision changes, white patches inside the mouth, dry mouth, sensitivity to spicy foods, fatigue, muscle weakness, chronic pain, etc. GvHD diagnosis can be challenging and include several procedures and tests, although GvHD can often be identified only by symptoms. The tests most frequently used to confirm GvHD include skin, gastrointestinal, liver, and lung biopsies.
The increasing prevalence of blood cancer along with the inflating number of bone marrow transplants to treat such condition is primarily driving the graft vs host disease market. In addition to this, the widespread adoption of corticosteroids as a front-line therapy owing to their proven safety and efficacy is also bolstering the market growth. Moreover, several key players are making significant R&D investments in developing biological and patented small-molecule immunosuppressive therapies that are tailored to conditioning and transplant type. This, in turn, is further acting as a significant growth-inducing factor. Besides this, the ongoing development of novel therapeutic approaches that are aimed at targeting T-cell responses or signaling pathways is also creating a positive outlook for the market. Additionally, the emerging popularity of extracorporeal photopheresis, a leukapheresis-therapeutical approach that works by altering the function of lymphocytes in the blood, for treating the ailment is further augmenting the market growth. Apart from this, the introduction of innovative drug candidates that aid in overcoming the steroid resistance associated with the disease is also expected to drive the graft vs host disease market in the coming years.
IMARC Group's new report "Graft vs Host Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast" provides an exhaustive analysis of the Graft vs Host Disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The report provides an in-depth understanding of current and future landscape of the Graft vs Host Disease market. This includes treatment practices, in-market and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool for Graft vs Host Disease across the seven major markets. According to the report the United States has the largest patient pool for Graft vs Host Disease and also represents the largest market for Graft vs Host Disease treatment. Furthermore, the current Graft vs Host Disease treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Graft vs Host Disease market in any manner.
Time Period of the Study
This report also provides a detailed analysis of the current Graft vs Host Disease marketed drugs and late-stage pipeline drugs.
Current Treatment Scenario, Marketed Drugs and Emerging Therapies
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at